Have a feature idea you'd love to see implemented?
Let us know!
ARQT Arcutis Biotherapeutics Inc
Price (delayed)
$10.24
Market cap
$1.2B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.66
Enterprise value
$1.27B
Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent
Highlights
The company's revenue has surged by 183% YoY and by 5% QoQ
ARQT's gross profit has surged by 171% year-on-year
Arcutis Biotherapeutics's quick ratio has shrunk by 71% QoQ and by 62% YoY
Arcutis Biotherapeutics's equity has decreased by 16% QoQ
Key stats
What are the main financial stats of ARQT
Market
Valuations
Earnings
Shares outstanding
117.04M
Market cap
$1.2B
Enterprise value
$1.27B
Price to earnings (P/E)
N/A
Price to book (P/B)
7.64
Price to sales (P/S)
9.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.16
Revenue
$138.71M
EBIT
-$165.81M
EBITDA
-$162.89M
Free cash flow
-$167.8M
Per share
Balance sheet
Liquidity
EPS
-$1.66
Free cash flow per share
-$1.35
Book value per share
$1.34
Revenue per share
$1.12
TBVPS
$3.44
Total assets
$437.35M
Total liabilities
$280.71M
Debt
$208.18M
Equity
$156.64M
Working capital
$251.29M
Debt to equity
1.33
Current ratio
2.46
Quick ratio
2.27
Net debt/EBITDA
-0.45
Margins
Efficiency
Dividend
EBITDA margin
-117.4%
Gross margin
89.6%
Net margin
-141%
Operating margin
-131.2%
Return on assets
-46%
Return on equity
-119.1%
Return on invested capital
-39.4%
Return on capital employed
-62.6%
Return on sales
-119.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ARQT stock price
How has the Arcutis Biotherapeutics stock price performed over time
Intraday
0.59%
1 week
3.12%
1 month
23.23%
1 year
441.8%
YTD
217.03%
QTD
10.11%
Financial performance
How have Arcutis Biotherapeutics's revenue and profit performed over time
Revenue
$138.71M
Gross profit
$124.24M
Operating income
-$181.93M
Net income
-$195.54M
Gross margin
89.6%
Net margin
-141%
The company's revenue has surged by 183% YoY and by 5% QoQ
ARQT's gross profit has surged by 171% year-on-year
The operating margin has soared by 74% YoY and by 3.6% from the previous quarter
Arcutis Biotherapeutics's net margin has surged by 74% YoY and by 6% QoQ
Growth
What is Arcutis Biotherapeutics's growth rate over time
Valuation
What is Arcutis Biotherapeutics stock price valuation
P/E
N/A
P/B
7.64
P/S
9.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.16
ARQT's EPS has soared by 62% YoY and by 19% QoQ
The stock's price to book (P/B) is 58% more than its 5-year quarterly average of 4.8 and 49% more than its last 4 quarters average of 5.1
Arcutis Biotherapeutics's equity has decreased by 16% QoQ
The company's revenue has surged by 183% YoY and by 5% QoQ
The price to sales (P/S) is 17% higher than the last 4 quarters average of 7.8
Efficiency
How efficient is Arcutis Biotherapeutics business performance
ARQT's ROS has soared by 75% YoY and by 4.4% QoQ
The ROE has grown by 47% YoY and by 18% from the previous quarter
ARQT's return on assets is up by 38% year-on-year and by 10% since the previous quarter
The company's return on invested capital rose by 28% YoY
Dividends
What is ARQT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ARQT.
Financial health
How did Arcutis Biotherapeutics financials performed over time
ARQT's total assets is 56% greater than its total liabilities
The current ratio has plunged by 71% from the previous quarter and by 63% YoY
Arcutis Biotherapeutics's quick ratio has shrunk by 71% QoQ and by 62% YoY
Arcutis Biotherapeutics's debt is 33% higher than its equity
ARQT's debt to equity has dropped by 70% year-on-year but it is up by 20% since the previous quarter
Arcutis Biotherapeutics's equity has decreased by 16% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.